Search Bar & Filters
Found 60 Actively Recruiting clinical trials
Actively Recruiting
This trial investigates treatment options for patients with microsatellite stable MSS or proficient mismatch repair pMMR metastatic colorectal cancer who do not have active liver metastases. It is a phase II, prospective, randomized, open-label study conducted across multiple centers. The study aims to evaluate the effectiveness of Fruquintinib combined with Tislelizumab compared to a control treatment in this specific patient group. Participants will be randomly assigned to one of two groups. One group will receive Fruquintinib orally once daily for 21 days in a 28-day cycle along with Tislelizumab given intravenously every 42 days. The other group will receive Trifluridinetipiracil orally twice daily on specific days of a 28-day cycle plus Bevacizumab intravenously every 14 days. Treatment will continue until disease progression, unacceptable side effects, patient choice, or a maximum of 15 months. During the study, patients will undergo regular assessments including imaging scans to monitor disease status, evaluations of side effects, and quality of life measures. Follow-up will continue for up to 18 months after the last patient begins treatment or until death, withdrawal, or loss to follow-up. Researchers will primarily measure the efficacy of the Fruquintinib and Tislelizumab combination, along with overall survival, response rates, safety, and quality of life.
Actively Recruiting
Researchers are investigating new treatments for advanced renal cell carcinoma RCC that has returned after prior therapy. The study aims to find out if the combination of belzutifan and zanzalintinib can help people with recurrent advanced RCC live longer without their cancer worsening compared to the drug cabozantinib. This is a phase 3 randomized trial evaluating these treatments in participants who have experienced recurrence during or after prior anti-PD-1L1 therapy. Participants are randomly assigned to receive either belzutifan plus zanzalintinib taken orally once daily or cabozantinib taken orally once daily. They continue their assigned treatment until certain reasons require stopping the study intervention. The study compares the effects of these treatments on cancer progression and survival among people with advanced RCC who have had disease recurrence after adjuvant therapy. During the study, participants will be regularly monitored for progression-free survival and overall survival for up to about 73 months. Researchers will also assess tumor response, duration of response, adverse events, and quality of life using questionnaires over approximately 25 months. The study involves ongoing evaluations to understand how these treatments affect symptoms, functioning, and overall health during long-term follow-up.
Actively Recruiting
Researchers are investigating new treatments for people with high-risk non-muscle invasive bladder cancer HR NMIBC, a type of bladder cancer that affects the inner lining and has not spread to the muscle. This condition includes carcinoma in situ CIS, a flat cancer limited to the bladders surface. The study aims to find out if adding intismeran autogene to the standard Bacillus Calmette-Guerin BCG treatment can help patients live longer without their cancer growing, spreading, or returning. Participants receive either intismeran autogene combined with BCG or BCG alone. Intismeran autogene is given as a 1 mg intramuscular injection every 3 weeks for nine doses. BCG is administered as a 50 mg intravesicular instillation once weekly for 6 weeks initially, then during weeks 13-15, 25-27, 49-51, and 73-75. Some participants receive only intismeran autogene. The study follows these treatments in separate groups to compare outcomes. During the study, participants undergo assessments over up to approximately five years to measure event-free survival, recurrence-free survival, disease-specific survival, overall survival, and other health outcomes. Researchers track cancer response, monitor adverse events, and evaluate how long participants remain cancer-free. Regular visits and tests help monitor safety and treatment effects throughout the study period.
Actively Recruiting
Researchers are evaluating tulisokibart as a treatment for radiographic axial spondyloarthritis r-axSpA, a type of arthritis causing pain, stiffness, and inflammation in the spine and pelvis joints. This condition leads to damage visible on X-rays. The study aims to find out if different doses of tulisokibart improve symptoms better than a placebo, which looks like the medicine but contains no active drug. Participants will be assigned to one of four groups a high dose, medium dose, low dose of tulisokibart, or a placebo. After 16 weeks, those on the low dose or placebo will be randomly reassigned to receive either the medium or high dose. The study includes a 16-week placebo-controlled period followed by a 124-week long-term extension, which consists of a 40-week main extension and an 84-week optional extension. Tulisokibart is given through subcutaneous injections. During the study, participants will undergo assessments of their arthritis symptoms using various scales and imaging, including MRI scans of the spine and pelvis. Researchers will monitor changes in pain, function, disease activity, and fatigue at baseline and after 16 weeks. Safety will be tracked throughout the study and for up to about 154 weeks. The study is scheduled to complete in early 2030.
Actively Recruiting
Researchers are comparing how long adults with moderate to severe active rheumatoid arthritis RA continue treatment with Upadacitinib UPA versus tumor necrosis factor inhibitors TNFi under real-world conditions in Germany. This observational study includes about 678 participants across approximately 80 sites and aims to understand treatment persistence over time. Participants will receive either Upadacitinib or a TNFi as prescribed by their doctors according to local labels and standard care practices. The choice of treatment is made independently of the study, and the study does not assign treatments but observes patients receiving these therapies in routine care. During the study, participants will be followed for up to 24 months to monitor how long they continue their prescribed treatment. Researchers will collect data on treatment retention rates and other health information during this period. The total study duration, including recruitment and follow-up, is about 48 months.
Actively Recruiting
This research aims to evaluate the effectiveness, safety, and tolerability of combining baxdrostat with dapagliflozin compared to dapagliflozin alone in people with chronic kidney disease CKD and high blood pressure. The goal is to reduce the risk of serious kidney problems, heart failure events, or cardiovascular death. This is a phase III, international, multicenter, randomized, double-blind, placebo-controlled, event-driven study focused on treatment outcomes. Participants who do not already use SGLT2 inhibitors will first undergo a 4-week dapagliflozin run-in period. After that, they will be randomly assigned to receive either baxdrostat plus dapagliflozin or placebo plus dapagliflozin. Baxdrostat dosing may start low and be increased if needed. Study visits will occur frequently early on at 2, 4, 8, 16, 34, and 52 weeks post-randomization, then approximately every 4 months. The study will end when a predetermined number of kidney or cardiovascular events occur. During the study, participants will have scheduled visits for assessments including kidney function, heart health, and safety monitoring. If they stop the study treatment early, they will continue on dapagliflozin alone and remain in the trial for follow-up visits. Researchers will measure outcomes such as sustained kidney function decline, kidney failure, heart failure events, cardiovascular death, and all-cause death over up to 37 months. Data collection continues until the study closes, with safety and tolerability closely observed throughout.
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
Actively Recruiting
Researchers are studying the safety, tolerability, how the body processes, and potential disease-modifying effects of a drug called BMS-986528 in adults with refractory, difficult-to-treat rheumatoid arthritis RA. This early-phase trial aims to gather initial data on the drugs impact in this group of patients. The study is sponsored by Bristol-Myers Squibb and focuses on participants aged 18 to 65 with this challenging form of RA. Participants receive specified doses of BMS-986528 on certain days during the trial. The study includes multiple experimental cohorts, each receiving the drug under close monitoring. Throughout the treatment period, various measurements are taken to assess how the drug behaves in the body, including concentrations and clearance, as well as its effects on immune cells and antibody levels. During the study, participants are regularly assessed for any treatment-emergent side effects and serious adverse events up to week 54. Researchers also evaluate changes in disease activity scores and immune system markers. These evaluations involve blood tests and clinical assessments to monitor safety and potential benefits. The entire participation period extends up to approximately 54 weeks, allowing for comprehensive observation.
Actively Recruiting
Researchers are evaluating saruparib AZD5305 added to standard radiation therapy RT and androgen deprivation therapy ADT compared to placebo in men with high-risk and very high-risk localized or locally advanced prostate cancer who have a BRCA1 or BRCA2 gene mutation. This Phase III randomized, double-blind, placebo-controlled study aims to assess whether saruparib improves metastasis-free survival in this specific group of patients. Participants will be divided into two groups Cohort A includes men with newly diagnosed high-risk prostate cancer or high-risk biochemical recurrence after radical prostatectomy, receiving saruparib or placebo with ADT Cohort B includes men with very high-risk prostate cancer receiving saruparib or placebo combined with ADT plus abiraterone and prednisoloneprednisone. Saruparib and placebo are given orally, alongside standard treatments, and participants will receive the treatment and follow-up according to their assigned cohort. During the study, participants will undergo scans including CT or MRI, bone scans, and PSMA-PET to monitor disease status. Researchers will track survival outcomes, metastasis-free survival up to about 93 months, and overall survival up to 11 years. Blood samples will measure drug concentrations, and safety will be monitored through adverse event reporting. Participants will be followed until the study ends, with ongoing assessments to evaluate treatment effects and safety.
1-10 of 60
1